OncoMatch/Clinical Trials/NCT06974929
A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer
Is NCT06974929 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including HRS-6209 Capsules and Letrozole Tablets for breast cancer.
Treatment: HRS-6209 Capsules · Letrozole Tablets · HRS-2189 Tablets — This is a study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HRS-6209 combined with other treatment regimens in breast cancer patients, and preliminarily observe its anti-tumor efficacy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic anti-tumor therapy
Evidence of radiographic disease progression during or after the last systemic anti-tumor therapy prior to the first study drug administration
Cannot have received: surgery
The patients received surgery...within 4 weeks before the first medication
Cannot have received: chemotherapy
The patients received...chemotherapy...within 4 weeks before the first medication
Cannot have received: immunotherapy
The patients received...immunotherapy...within 4 weeks before the first medication
Cannot have received: macromolecular targeted therapy
The patients received...macromolecular targeted therapy within 4 weeks before the first medication
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify